Year: 2016
Type: article
Study design: Observational Study
Abstract: We characterized a unique group of patients with neuromyelitis optica spectrum disorder (NMOSD) who carried autoantibodies of aquaporin-4 (AQP4) and myelin-oligodendrocyte glycoprotein (MOG). Among the 125 NMOSD patients, 10 (8.0%) were AQP4- and MOG-ab double positive, and 14 (11.2%) were MOG-ab single positive. The double-positive patients had a multiphase disease course with a high annual relapse rate (P=0.0431), and severe residual disability (P>0.0001). Of the double- positive patients, 70% had MS-like brain lesions, more severe edematous, multifocal regions on spinal magnetic resonance imaging (MRI), pronounced decreases of retinal nerve fiber layer thickness and atrophy of optic nerves. In contrast, patients with only MOG-ab had a higher ratio of monophasic disease course and mild residual disability. Spinal cord MRI illustrated multifocal cord lesions with mild edema, and brain MRIs showed more lesions around lateral ventricles. NMOSD patients carrying both autoantibodies to AQP4 and MOG existed and exhibited combined features of prototypic NMO and relapsing- remitting form of MS, whereas NMOSD with antibodies to MOG only exhibited an "intermediate" phenotype between NMOSD and MS. Our study suggests that antibodies against MOG might be pathogenic in NMOSD patients and that determination of anti-MOG antibodies maybe instructive for management of NMOSD patients.
Source: Science China Life Sciences
Authors: Yaping Yan, Yujing Li, Ying Fu, Li Yang, Lei Su, Kaibin Shi, Minshu Li, Qiang Liu, Aimee Borazanci, Yaou Liu, Yong He, Jeffrey L. Bennett, Timothy L. Vollmer, Fu-Dong Shi
Institutions: Tianjin Medical University General Hospital, Tianjin Medical University, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Beijing Normal University, State Key Laboratory of Cognitive Neuroscience and Learning, University of Colorado Anschutz, University of Colorado Denver
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,790
OpenAlex ID: W2286801180
